DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $23.78 billion. The enterprise value is $22.75 billion.
| Market Cap | 23.78B |
| Enterprise Value | 22.75B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 385.87 million shares outstanding. The number of shares has decreased by -2.04% in one year.
| Current Share Class | 385.87M |
| Shares Outstanding | 385.87M |
| Shares Change (YoY) | -2.04% |
| Shares Change (QoQ) | -1.33% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 96.56% |
| Float | 383.92M |
Valuation Ratios
The trailing PE ratio is 26.36 and the forward PE ratio is 23.30. DexCom's PEG ratio is 1.09.
| PE Ratio | 26.36 |
| Forward PE | 23.30 |
| PS Ratio | 4.94 |
| Forward PS | 4.35 |
| PB Ratio | 8.04 |
| P/TBV Ratio | 8.29 |
| P/FCF Ratio | 16.64 |
| P/OCF Ratio | 13.34 |
| PEG Ratio | 1.09 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.61, with an EV/FCF ratio of 15.92.
| EV / Earnings | 24.45 |
| EV / Sales | 4.72 |
| EV / EBITDA | 17.61 |
| EV / EBIT | 22.02 |
| EV / FCF | 15.92 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.47.
| Current Ratio | 1.95 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 1.04 |
| Debt / FCF | 0.97 |
| Interest Coverage | 61.88 |
Financial Efficiency
Return on equity (ROE) is 35.62% and return on invested capital (ROIC) is 39.25%.
| Return on Equity (ROE) | 35.62% |
| Return on Assets (ROA) | 9.65% |
| Return on Invested Capital (ROIC) | 39.25% |
| Return on Capital Employed (ROCE) | 23.44% |
| Weighted Average Cost of Capital (WACC) | 11.33% |
| Revenue Per Employee | $434,045 |
| Profits Per Employee | $83,820 |
| Employee Count | 11,100 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 3.01 |
Taxes
In the past 12 months, DexCom has paid $273.20 million in taxes.
| Income Tax | 273.20M |
| Effective Tax Rate | 22.70% |
Stock Price Statistics
The stock price has decreased by -28.77% in the last 52 weeks. The beta is 1.40, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -28.77% |
| 50-Day Moving Average | 63.23 |
| 200-Day Moving Average | 68.16 |
| Relative Strength Index (RSI) | 50.79 |
| Average Volume (20 Days) | 5,421,090 |
Short Selling Information
The latest short interest is 18.32 million, so 4.75% of the outstanding shares have been sold short.
| Short Interest | 18.32M |
| Short Previous Month | 15.19M |
| Short % of Shares Out | 4.75% |
| Short % of Float | 4.77% |
| Short Ratio (days to cover) | 4.34 |
Income Statement
In the last 12 months, DexCom had revenue of $4.82 billion and earned $930.40 million in profits. Earnings per share was $2.34.
| Revenue | 4.82B |
| Gross Profit | 2.96B |
| Operating Income | 1.03B |
| Pretax Income | 1.20B |
| Net Income | 930.40M |
| EBITDA | 1.29B |
| EBIT | 1.03B |
| Earnings Per Share (EPS) | $2.34 |
Balance Sheet
The company has $2.42 billion in cash and $1.38 billion in debt, with a net cash position of $1.03 billion or $2.67 per share.
| Cash & Cash Equivalents | 2.42B |
| Total Debt | 1.38B |
| Net Cash | 1.03B |
| Net Cash Per Share | $2.67 |
| Equity (Book Value) | 2.96B |
| Book Value Per Share | 7.66 |
| Working Capital | 2.11B |
Cash Flow
In the last 12 months, operating cash flow was $1.78 billion and capital expenditures -$353.10 million, giving a free cash flow of $1.43 billion.
| Operating Cash Flow | 1.78B |
| Capital Expenditures | -353.10M |
| Depreciation & Amortization | 258.90M |
| Net Borrowing | -1.21B |
| Free Cash Flow | 1.43B |
| FCF Per Share | $3.70 |
Margins
Gross margin is 61.50%, with operating and profit margins of 21.45% and 19.31%.
| Gross Margin | 61.50% |
| Operating Margin | 21.45% |
| Pretax Margin | 24.98% |
| Profit Margin | 19.31% |
| EBITDA Margin | 26.82% |
| EBIT Margin | 21.45% |
| FCF Margin | 29.67% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.04% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 3.91% |
| FCF Yield | 6.01% |
Analyst Forecast
The average price target for DexCom is $84.67, which is 37.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $84.67 |
| Price Target Difference | 37.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 10.48% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 6.83 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.83 |
| Piotroski F-Score | 7 |